Gene therapy company pulls in another $150M to continue scale-up
The company has raised more than $600 million, a runway it expects to take it into late 2026. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 26, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
RTP gene therapy firm adds $150M in funding
Kriya will use an additional $150 million to advance its gene therapy programs. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 26, 2023 Category: Biotechnology Authors: Zac Ezzone Source Type: news
Cheaper, more accessible cell, gene therapies? Nobel winner's task force points the way
A task force assembled by Nobel Prize winner Jennifer Doudna's Innovative Genomics Institute proposes a way to lower the multimillion-dollar price of innovative cell and gene therapies and make those treatments more accessible to more people.
The 30-person task force, which met for a year, said in a report that a "mixed organizational model" of an academic institution, a nonprofit medical research organization and a public benefit corporation could oversee fundraising and research, manage manufacturing … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 25, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Passage Bio reduces staff by 26% in latest round of job cuts
The job cuts at Philadelphia gene therapy developer Passage Bio include the company's CFO and chief technical officer. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 24, 2023 Category: Biotechnology Authors: John George Source Type: news
Gene therapy eyedrops restored a boy's sight. Similar treatments could help millions
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Dr. Alfonso Sabater pulled up two photos of Antonio Vento Carvajal's eyes. One showed cloudy scars covering both…#sciencex #alfonsosabater #antonioventocarvajal #spanish #cuba #yeah #krystalbiotech #sumakrishnan #pittsburgh #vyjuvek (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2023 Category: Consumer Health News Source Type: news
Gene therapy eyedrops restored a boy's sight. Similar treatments could help millions
Antonio Vento Carvajal has been legally blind for much of his 14 years (Source: ABC News: Health)
Source: ABC News: Health - July 24, 2023 Category: Consumer Health News Tags: Health Source Type: news
America will struggle to pay for ultra-expensive gene therapies
T is familiar, the liquid inside could be water—but the price tag is a little more unusual. A shot of Zolgensma, a gene therapy for spinal-muscular atrophy, comes to $2.1m. It is one of a new generation of ultra-expensive medicines. Treatments for beta-thalassemia and haemophilia, two blood…#zolgensma #haemophilia #vertex #medicaid #michaelkleinrock #franciscollins #innovationcentre #zandyforbes #meirax #hepatitis (Source: Reuters: Health)
Source: Reuters: Health - July 22, 2023 Category: Consumer Health News Source Type: news
5 takeaways from POLITICO ’s Next Generation of Health Care Therapies Event
Therapies that change genes are spurring innovative treatments for intractable diseases. The Food and Drug Administration has approved eight gene therapies in the past year and a half, including one last month to treat a rare muscular disorder. More are under review. POLITICO invited experts,…#ericacischke #cischke #anniekennedy #fda #petermarks #marks #operationwarpspeed #medicare #medicaid #carlarodriguezwatson (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2023 Category: Consumer Health News Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Investor Update - July 20, 2023 Category: Pharmaceuticals Source Type: news
Spark 3.0? Local gene therapy pioneer levels up with growing construction and new product pipelines
Spark Therapeutics' growth accelerated when it became part of a global health care company with deep pockets and a willingness to spend on innovation. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2023 Category: Biotechnology Authors: John George Source Type: news
Delivering Gene Therapies in Utero
By delivering mRNA to the skin of mice in utero, researchers showed a proof-of-concept for shuttling gene therapies to skin cells before birth. (Source: The Scientist)
Source: The Scientist - July 18, 2023 Category: Science Tags: News & Opinion Source Type: news
In New Era of Gene Therapy, PCPs Are'Boots on the Ground'In New Era of Gene Therapy, PCPs Are'Boots on the Ground '
As the number of gene-based therapies grows, primary care clinicians will be expected to know ever more about how to manage patients after treatment.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - July 18, 2023 Category: Pediatrics Tags: Pediatrics News Source Type: news
Gene Therapy Promising for Hereditary Vision Loss Gene Therapy Promising for Hereditary Vision Loss
Patients with a progressive form of Leber hereditary optic neuropathy (LHON) that causes rapid vision loss experienced improvement in their eyesight with an experimental gene therapy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 13, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
US Watchdog Lifts Price Estimate for Gene Therapies US Watchdog Lifts Price Estimate for Gene Therapies
An influential US drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio for sickle cell disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
